Parallax Volatility Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parallax Volatility Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19,265	Closed	-$40K	–	3114
2022 Q1	$40K	Sell	19,265 -16,272	-46%	-$45.1K	﹤0.01%	2510
2021 Q4	$140K	Buy	+35,537	New	+$173K	﹤0.01%	2542
2021 Q3	–	Sell	-33,333	Closed	-$153K	–	3248
2021 Q2	$153K	Buy	+33,333	New	+$161K	﹤0.01%	2501
2019 Q2	–	Sell	-78,389	Closed	-$436K	–	3279
2019 Q1	$436K	Buy	+78,389	New	+$476K	﹤0.01%	1589
2018 Q1	–	Sell	-6,510	Closed	-$64K	–	3418
2017 Q4	$64K	Sell	6,510 -344,079	-98%	-$3.58M	﹤0.01%	3073
2017 Q3	$4.31M	Buy	+350,589	New	+$5.18M	0.01%	608

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallax Volatility Advisers's LXRX Position: Q2 2022 in Review

Parallax Volatility Advisers sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2022, closing a stake of 19,265 shares — an estimated $40K sold.

Parallax Volatility Advisers first reported a position in LXRX in Q3 2017 and held it in 6 quarters. The position peaked at $4.31M in Q3 2017. 86 funds tracked by Wall St. Rank hold LXRX as of Q2 2022.

Parallax Volatility Advisers reported no remaining Lexicon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 19,265 Lexicon Pharmaceuticals shares in Q2 2022, an estimated $40K.
Parallax Volatility Advisers first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Parallax Volatility Advisers's Lexicon Pharmaceuticals position peaked at $4.31M in Q3 2017.
86 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2022.

Based on Parallax Volatility Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.